Friday 12 December 2014

Melanoma & Skin Cancer News Round Up: 12/12/2014


MASScot does not endorse nor is affiliated with any of the content contained within these links.

  • Experimental drugs aim to tackle melanoma 'escape route'

Manchester researchers are developing a new generation of targeted melanoma drugs that could bypass treatment resistance seen with current therapies.

Source: CR UK


  • Ocular Melanoma: Are You Aware of This Eye Cancer? (US)


I never even knew ocular melanoma existed. I was aware of skin cancer, but never knew that people could get cancer in their eyes. The fact is that not many people do. Ocular melanoma is a very rare cancer, with only about six in 1 million people diagnosed per year.

Source: Huffington Post 


  • Study finds melanoma and prostate cancer a risk for firefighters (AUS)

Firefighters are at greater risk of developing some cancers, compared to the Australian public, a study has found.

Source: Medical Xpress 


  • Choroidal Melanoma in Children: Be Aware of Risks

The authors describe a case of choroidal melanoma in a 13-year-old girl treated with plaque brachytherapy.

Source: Healio 

Tragedy as man, 24, dies just eight months after doctors diagnosed skin cancer in mole triggered by Turkish holiday

A man who developed skin cancer after getting sunburnt in Turkey has died - just 18 months after returning from his holiday. 

Source: Daily Mail 


  • New targeted drugs could treat drug-resistant skin cancer

A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports.

Source: Eurekalert 


  • Science & Society: Sunlight, sunbeds and skin cancer (US)

One American dies every hour from melanoma, the most common of the skin cancers. And a major tragedy is it is largely preventable.

But “everyone knows” it’s due to exposure to sunlight, so why devote a column to it at the beginning of winter? I assure you, there are reasons.

Source: Herald Extra 


No comments:

Post a Comment